Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma

Author： Foss Francine M  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.7, Iss.9, 2011-09, pp. : 1141-1152

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pralatrexate: evaluation of clinical efficacy and toxicity in T-cell lymphoma

By Shimanovsky Alexei   Dasanu Constantin A  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 4, 2013-03 ,pp. : 515-523

Informa Healthcare

Access to resources Recommend Favorite

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma

By Dondi Alessandra   Bari Alessia   Pozzi Samantha   Ferri Paola   Sacchi Stefano  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 5, 2014-05 ,pp. : 711-718

Informa Healthcare

Access to resources Recommend Favorite

Romidepsin: In the Treatment of T-Cell Lymphoma

By Yang Lily P.H.  

Drugs, Vol. 71, Iss. 11, 2011-07 ,pp. : 1469-1480

Adis International

Access to resources Recommend Favorite

CD20-positive T-cell Lymphoma with Indolent Clinical Behaviour

By Xiao W-B   Wang Z-M   Wang L-J  

The Journal of International Medical Research, Vol. 38, Iss. 3, 2010-06 ,pp. : 1170-1174

Field House Publishing

Access to resources Recommend Favorite

Panobinostat is promising for the treatment of patients with cutaneous T-cell lymphoma

By  

Inpharma, Vol. 1, Iss. 1653, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite